Shorena Archuadze
机构：Boehringer Ingelheim (Germany)
发表论文 31 篇 · 总被引 18 次 · h-index 2
代表论文
- A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers. (2023 · Journal of Clinical Oncology · 被引 10)
- A phase I first in human, open-label, multicenter study of BI3706674, KRAS multi-inhibitor, monotherapy in patients with advanced solid tumors bearing KRAS WT amp. (2026 · Journal of Clinical Oncology · 被引 3)
- BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings (2026 · Cancer Research Communications · 被引 2)
- A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers. (2023 · Journal of Clinical Oncology · 被引 2)
- Table 4 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings (2026)
- Table 5 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings (2026)